Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

55.55
+1.071.96%
Post-market: 55.47-0.0800-0.14%16:00 EDT
Volume:998.48K
Turnover:55.11M
Market Cap:5.30B
PE:-12.73
High:55.65
Open:55.06
Low:53.62
Close:54.48
52wk High:63.95
52wk Low:26.74
Shares:95.43M
Float Shares:89.89M
Volume Ratio:0.76
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3646
EPS(LYR):-4.3646
ROE:-51.76%
ROA:-32.58%
PB:9.11
PE(LYR):-12.73

Loading ...

Press Release: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Jan 17

Xenon Pharmaceuticals: Undervalued ‘Pipeline-in-a-Drug’ Story with Blockbuster Potential Ahead of Key 2026 Readouts

TIPRANKS
·
Jan 14

Xenon Pharmaceuticals: Advancing Late-Stage Epilepsy and Depression Programs and Expanding NaV1.7/Kv7 Pipeline Support Buy Rating and $55 Target

TIPRANKS
·
Jan 13

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Xenon (XENE)

TIPRANKS
·
Jan 11

Xenon Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Jan 09

Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares

Reuters
·
Jan 03

Biohaven Misses The Mark In Depression Trial, Stock Falls

Benzinga_recent_news
·
Dec 26, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks

Reuters
·
Dec 17, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse

Reuters
·
Dec 17, 2025

BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026

Reuters
·
Dec 17, 2025

BRIEF-Eles Says Xenon Increases to 2.95 Eur/Shr Its Offer Price For Eles Bid

Reuters
·
Dec 15, 2025

BRIEF-Eles Says Market Regulator Consob Has Approved Xenon Offer Document

Reuters
·
Dec 15, 2025

Xenon Pharmaceuticals Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Dec 12, 2025

Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares

Reuters
·
Dec 10, 2025

Xenon Pharmaceuticals Reports 48-Month Azetukalner Study Shows 90.9% Seizure Reduction in Epilepsy Patients

Reuters
·
Dec 05, 2025

Xenon Pharmaceuticals Grants Equity Inducements to New Employees

Reuters
·
Dec 05, 2025

Press Release: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Dec 05, 2025

Xenon Pharmaceuticals CEO Ian Mortimer Reports Sale of Common Shares

Reuters
·
Dec 04, 2025

Xenon Pharmaceuticals to Present Azetukalner and Epilepsy Data at AES 2025 Webinar

Reuters
·
Dec 03, 2025

Xenon Pharmaceuticals (XENE): Evaluating Valuation as New Epilepsy and Dravet Data Draw Investor Attention

Simply Wall St.
·
Nov 28, 2025